NEWSROOM
News Articles

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced…

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced…

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced…

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay’s clinical development programs and provide strategic medical and scientific leadership to the Company.

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results
ACTON, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost…